February 1, 2005
Mountain View, CA

Cambrios Technologies Corporation, the pioneer in applying strategies of biological  systems to the assembly and synthesis of materials for solid-state electronics, announced today the first closing of $9 million toward a guaranteed $12 million  Series B funding round.

In-Q-Tel,  Harris & Harris Group Inc., (Nasdaq: TINY) and Headland Ventures join  Series A investors Alloy Ventures, ARCH Venture Partners, Avalon Ventures, Lux  Capital, and Oxford Bioscience Partners, all of whom are participating in the  Series B. Cambrios will use the new funds to accelerate its development of  biochemical materials for electronic manufacturing processes and other  commercial products.

"Cambrios  has a large vision for using biological technology in assembling inorganic  materials that make up solid-state electronic devices," said Michael  Knapp, Ph.D., president and CEO of Cambrios. "Our investors have given us  a great vote of confidence. We now have the resources to pursue this vision  vigorously and accomplish two things: rapidly develop tangible manifestations  of the technology and find commercialization partners with which to bring them  to market."

"We're  pleased to be investors in Cambrios," said Daniel Leff, Executive Vice  President & Managing Director at Harris & Harris Group. "Cambrios'  approach of liquid-phase, biologically directed, inorganic materials synthesis  has the potential to be a more cost-effective fabrication alternative for a  multitude of electronics applications, such as the deposition of thin films in  liquid crystal display manufacturing."

"It's  still early but if Cambrios continues hitting key milestones, it could effect  one of the most profound shifts in the history of electronics  manufacturing," said Josh Wolfe, Co-Founder and Managing Partner with Lux  Capital.

About Harris & Harris  Group, Inc.
The  Harris & Harris Group   is a publicly traded venture capital company that now makes initial investments  exclusively in tiny technology, including nanotechnology, microsystems and  microelectromechanical systems (MEMS). The Company's last 19 initial private  equity investments have been in tiny-technology enabled companies. The Company  has 17,248,845 common shares outstanding.

About Headland Ventures
Headland  Ventures is a venture partnership singularly focused on building successful  companies from the ground up. Headland concentrates on the connectivity  provided by the next generation communications network and the companies  defining its direction.

About Cambrios Technologies  Corporation
Cambrios was founded in 2002 as Semzyme, Inc. based on the work of Angela Belcher Ph.D.,  a professor at MIT and previously at University of Texas. The company's  headquarters and laboratories are located in Mountain View, Calif. Cambrios' technology and I.P. portfolio address the discovery of proteins that bind  important inorganic materials, the use of those biomolecules to assemble  nanostructures made of these materials, and the applications of these methods  in processes for the construction of solid-state electronic devices. Investors  in Cambrios include Alloy Ventures, ARCH Venture Partners, Avalon Ventures,  Harris & Harris, Headland Ventures, In-Q-Tel, Lux Capital, and Oxford  Biosciences.